Janux Therapeutics Inc Cash Flow Conversion Efficiency
Janux Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Janux Therapeutics Inc (JANX) has a cash flow conversion efficiency ratio of -0.013x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.34 Million) by net assets ($941.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Janux Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2025. This chart illustrates how Janux Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View JANX stock price for real-time trading data and today's change.
Janux Therapeutics Inc Cash Flow Conversion Ratio Explained
Janux Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Janux Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Janux Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Janux Therapeutics Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
JM AB (publ)
ST:JM
|
-0.005x |
|
Jaya Real Property Tbk
JK:JRPT
|
0.026x |
|
Cisen Pharmaceutical Co Ltd
SHG:603367
|
0.049x |
|
Run Long Construction Co Ltd
TW:1808
|
0.262x |
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
0.052x |
|
Mirle Automation Corp
TW:2464
|
-0.009x |
|
Guangzhou Fangbang Electronics Co Ltd
SHG:688020
|
0.018x |
|
Guangzhou Newlife New Material Co. Ltd. A
SHE:301323
|
N/A |
Annual Cash Flow Conversion Efficiency for Janux Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Janux Therapeutics Inc from 2019 to 2025. Review Janux Therapeutics Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $956.82 Million | $-82.23 Million | -0.086x | -100.63% |
| 2024-12-31 | $1.02 Billion | $-43.81 Million | -0.043x | +70.83% |
| 2023-12-31 | $344.35 Million | $-50.58 Million | -0.147x | -9.75% |
| 2022-12-31 | $320.74 Million | $-42.92 Million | -0.134x | -188.78% |
| 2021-12-31 | $366.33 Million | $-16.98 Million | -0.046x | -115.53% |
| 2020-12-31 | $-14.64 Million | $-4.37 Million | 0.298x | -38.06% |
| 2019-12-31 | $-7.94 Million | $-3.83 Million | 0.482x | -- |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in… Read more